Resistant Mycoplasma Pneumonia

Abstract

Mycoplasma pneumoniae is recognized as a leading cause of community-acquired lower respiratory tract infection in children, which accounts for about 25-30% of pneumonia in children. Macrolides are the first-line treatment for M. pneumoniae infections. However, the extensive use of macrolides in clinical practice has resulted in the emergence of macrolide-resistant M. pneumoniae (MRMP), which has a negative impact on treatment outcomes.  

Here we present a case of severe, Macrolide-resistant Mycoplasma pneumoniae infection in a previously healthy 9-year-old male, culminating in necrotizing pneumonia, complicated by bilateral pleural effusion. The case highlights the challenges in diagnosing and managing atypical pneumonia unresponsive to first-line therapies.